Advertisement

Virus Genes

, Volume 55, Issue 1, pp 22–32 | Cite as

Chimeric protein consisting of 3M2e and HSP as a universal influenza vaccine candidate: from in silico analysis to preliminary evaluation

  • Behrokh Farahmand
  • Najmeh Taheri
  • Hadiseh Shokouhi
  • Hoorieh Soleimanjahi
  • Fatemeh FotouhiEmail author
Article
  • 95 Downloads

Abstract

The 23-amino acid ectodomain of influenza virus M2 protein (M2e) is highly conserved among human influenza virus variants and represents an attractive target for developing a universal vaccine. Although this peptide has limited potency and low immunogenicity, the degree of M2e density has been shown to be a critical factor influencing the magnitude of epitope-specific responses. The aim of this study was to design a chimer protein consisting of three tandem repeats of M2e peptide sequence fused to the Leishmania major HSP70 gene and evaluate its characteristics and immunogenicity. The structure of the deduced protein and its stability, aliphatic index, biocomputed half-life and the anticipated immunogenicity were analyzed by bioinformatics software. The oligonucleotides encoding 3M2e and chimer 3M2e-HSP70 were expressed in Escherichia coli and affinity purified. The immunogenicity of the purified recombinant proteins was preliminary examined in mouse model. It was predicted that fusion of HSP70 to the C-terminal of 3M2e peptide led to increased stability, hydropathicity, continuous B cell epitopes and antigenic propensity score of chimer protein. Also, the predominant 3M2e epitopes were not hidden in the chimer protein. The initial in vivo experiment showed that 3M2e-HSP chimer protein stimulates specific immune responses. In conclusion, the results of the current study suggest that 3M2e-HSP chimer protein would be an effective universal subunit vaccine candidate against influenza infection.

Keywords

Fusion protein Influenza virus M2e HSP70 in silico Universal vaccine 

Notes

Acknowledgements

We would like to thank Dr. Masoumeh Tavassoti Kheiri and Dr. Reza Ahangari Cohan for kindly editing the manuscript.

Author Contributions

Fatemeh Fotouhi, Behrokh Farahmand and Najmeh Taheri designed the construct, performed the analysis and wrote the manuscript. Hadiseh Shokouhi evaluated immune responses. Fatemeh Fotouhi supervised this work. Hoorieh Soleimanjahi reviewed and approved the final manuscript.

Funding

This work was funded by Grant No. 759 from Pasteur Institute of IRAN.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving in animals participant

Pasteur Institute of Iran, Ethic code: IR.PII.REC.1394.39.

Supplementary material

11262_2018_1609_MOESM1_ESM.pdf (12 kb)
Supplementary material 1 (PDF 12 KB)

References

  1. 1.
    Khanna M, Sharma S, Kumar B, Rajput R (2014) Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development. BioMed Res Int.  https://doi.org/10.1155/2014/546274 Google Scholar
  2. 2.
    Munster VJ, Baas C, Lexmond P, Waldenstrom J, Wallensten A, Fransson T, Rimmelzwaan GF, Beyer W, Schutten M, Olsen B (2007) Spatial, temporal, and species variation in prevalence of influenza A viruses in wild migratory birds. PLoS Pathog 3(5):e61CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM (2004) Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 4:499–509CrossRefGoogle Scholar
  4. 4.
  5. 5.
    Frace AM, Klimov AI, Rowe T, Black RA, Katz JM (1999) Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17:2237–2244CrossRefGoogle Scholar
  6. 6.
    De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W (2006) The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24:544–551CrossRefGoogle Scholar
  7. 7.
    Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, Abed Y, Savard C, Pare C, Lopez Macias C, Boivin G, Leclerc D (2008) Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26:3340–3395CrossRefGoogle Scholar
  8. 8.
    Wu F, Huang JH, Yuan XY, Huang WS, Chen YH (2007) Characterization of immunity induced by M2e of influenza virus. Vaccine 25:8868–8873CrossRefGoogle Scholar
  9. 9.
    Zhang X, Liu M, Liu C, Du J, Shi W, Sun E, Li H, Li J, Zhang Y (2011) Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens. Intervirology 54:290–299CrossRefGoogle Scholar
  10. 10.
    Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Umlauf S, Tussey L, Powell TJ (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26:201–214CrossRefGoogle Scholar
  11. 11.
    Farzanehpour M, Soleimanjahi H, Hassan ZM, Amanzadeh A, Ghaemi A, Fazeli M (2013) HSP70 modified response against HPV based tumor. Eur Rev Med Pharmacol Sci 17:228–234Google Scholar
  12. 12.
    Li J, Li KN, Gao J, Cui JH, Liu YF, Yang SJ (2008) Heat shock protein 70 fused to or complexed with hantavirus nucleocapsid protein significantly enhances specific humoral and cellular immune responses in C57BL/6 mice. Vaccine 26:3175–3187CrossRefGoogle Scholar
  13. 13.
    Kaur J, Kaur T, Kaur S (2011) Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice. Acta Trop 119:50–56CrossRefGoogle Scholar
  14. 14.
    Doytchinova IA1, Flower DR (2007) VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform 8:4CrossRefGoogle Scholar
  15. 15.
    CombetC BlanchetC, Geourjon C, Deléage G (2000) NPS@: network protein sequence analysis. Trends Biochem Sci 25(3):147–150CrossRefGoogle Scholar
  16. 16.
    Schowed T, Kopp J, Guex N, Peitch MC (2003) SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acid Res 31(13):3381–3385CrossRefGoogle Scholar
  17. 17.
    Yang J, Zhang Y (2015) I-TASSER server: new development for protein structure and function predictions. Nucleic Acids Res 43(W1):W174–W181CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG, Richardson JS, Richardson DC (2003) Structure validation by calpha geometry: phi, psi and cbeta deviation. Proteins 50:437–450CrossRefGoogle Scholar
  19. 19.
    Ansari HR, Raghava GP (2010) Identification of conformational B-cell Epitopes in an antigen from its primary sequence. Immunome Res 6:6CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A et al (2008) ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinform 9(1):514.  https://doi.org/10.1186/1471-2105-9-514 CrossRefGoogle Scholar
  21. 21.
    Singh H, Raghava GP (2001) ProPred: prediction of HLA-DR binding sites. Bioinformatics 17:1236–1237CrossRefGoogle Scholar
  22. 22.
    Singh H, Raghava GP (2003) ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 19:1009–1014CrossRefGoogle Scholar
  23. 23.
    Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(5259):680–685CrossRefGoogle Scholar
  24. 24.
    Fotouhi F, Shaffifar M, Farahmand B, Shirian S, Saeidi M, Tabarraei A, Gorji A, Ghaemi A (2017) Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus. Arch Virol 162:1251–1260CrossRefGoogle Scholar
  25. 25.
    Shaw A (2011) Conserved proteins as potential universal vaccines. In: Rappuoli R, Del Giudice G (eds) Influenza vaccines for the future. Springer, Basel, pp 313–325CrossRefGoogle Scholar
  26. 26.
    Wang Y, Zhou L, Shi H, Xu H, Yao H, Xi XG, Toyoda T, Wang X, Wang T (2009) Monoclonal antibody recognizing SLLTEVET epitope of M2 protein potently inhibited the replication of influenza A viruses in MDCK cells. Biochem Biophys Res Commun 385:118–122CrossRefGoogle Scholar
  27. 27.
    Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR (1990) Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 64:1375–1377PubMedCentralGoogle Scholar
  28. 28.
    Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22:2993–3003CrossRefGoogle Scholar
  29. 29.
    Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5(10):1157–1163CrossRefGoogle Scholar
  30. 30.
    Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N (2008) A novel mucosal adjuvant targeted influenza vaccine. Vaccine 26:1243–1252CrossRefGoogle Scholar
  31. 31.
    Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, Wunner W, Couch RB, Gerhard W (2006) Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3:102CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Liu W, Chen YH (2005) High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins. Eur J Immunol 35:505–514CrossRefGoogle Scholar
  33. 33.
    Babapoor S, Neef T, Mittelholzer C, Girshick T, Garmendia A, Shang H, Khan MI, Burkhard P (2011) A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection. Influenza Res Treat 2011:126794Google Scholar
  34. 34.
    Kilic A, Mandal K (2012) Heat shock proteins: pathogenic role in atherosclerosis and potential therapeutic implications. Autoimmune Dis 2012:502813PubMedCentralGoogle Scholar
  35. 35.
    Ebrahimi SM, Dabaghian M, Tebianian M, Jazi MH (2012) In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Virology 430:63–72CrossRefGoogle Scholar
  36. 36.
    Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L (2007) Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Vaccine 25:4159–4169CrossRefGoogle Scholar
  37. 37.
    Crasto CJ, Feng JA (2000) LINKER: a program to generate linker sequences for fusion proteins. Protein Eng 13:309–312CrossRefGoogle Scholar
  38. 38.
    George RA, Heringa J (2002) An analysis of protein domain linkers: their classification and role in protein folding. Protein Eng 15:871–879CrossRefGoogle Scholar
  39. 39.
    Argos P (1990) An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion. J Mol Biol 211:943–958CrossRefGoogle Scholar
  40. 40.
    Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM, Shiver JW, Liang X, Joyce JG (2009) Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 27:1440–1447CrossRefGoogle Scholar
  41. 41.
    Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH, McCullers JA (2006) Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13(9):981–990CrossRefPubMedCentralGoogle Scholar
  42. 42.
    Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310:1510–1512CrossRefGoogle Scholar
  43. 43.
    Shokouhi H, Farahmand B, Ghaemiph A, Mazaheri V, Fotouhi F (2018) Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge. Virus Res 251:40–46CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Behrokh Farahmand
    • 1
  • Najmeh Taheri
    • 1
  • Hadiseh Shokouhi
    • 1
  • Hoorieh Soleimanjahi
    • 2
  • Fatemeh Fotouhi
    • 1
    Email author
  1. 1.Department of Influenza and Other Respiratory VirusesPasteur Institute of IranTehranIran
  2. 2.Department of VirologyTarbiat Modares UniversityTehranIran

Personalised recommendations